LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$21.86 USD
+1.21 (5.86%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $21.83 -0.03 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LENZ 21.86 +1.21(5.86%)
Will LENZ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LENZ
RTW Biotech half-year net asset value rises amid "challenging markets"
Lenz Therapeutics files to sell 1.58M shares of common stock for holders
LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024